Fortesta

Fortesta is a brand name of testosterone, approved by the FDA in the following formulation(s):

FORTESTA (testosterone - gel, metered; transdermal)

• 
  Manufacturer: ENDO PHARMS
  
  Approval date: December 29, 2010
  
  Strength(s): 10MG/0.5GM ACTIVATION ^[RLD]

Has a generic version of Fortesta been approved?

No. There is currently no therapeutically equivalent version of Fortesta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fortesta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Penetration enhancing and irritation reducing systems
  Patent 6,319,913
  Issued: November 20, 2001
  Inventor(s): Mak; Vivien H. W. & Grayson; Stephen
  Assignee(s): Cellegy Pharmaceuticals, Inc.
  This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied drugs and with the reduction of skin irritation that often accompanies transdermal and topical drug delivery.
  
  Patent expiration dates:
  
  
  • November 9, 2018
    
    ✓ 
    Patent use: TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
  
  



• 
  Penetration enhancing and irritation reducing systems
  Patent 6,579,865
  Issued: June 17, 2003
  Inventor(s): Vivien H. W.; Mak & Stephen; Grayson
  Assignee(s): Cellegy Pharmaceuticals, Inc.
  This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied drugs and with the reduction of skin irritation that often accompanies transdermal and topical drug delivery.
  
  Patent expiration dates:
  
  
  • November 9, 2018
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 29, 2013 - NEW PRODUCT
  
  

See also...

• Fortesta Consumer Information (Drugs.com)
• Fortesta Gel Consumer Information (Wolters Kluwer)
• Fortesta Consumer Information (Cerner Multum)
• Fortesta Advanced Consumer Information (Micromedex)
• Testosterone Consumer Information (Drugs.com)
• Testosterone Consumer Information (Wolters Kluwer)
• Testosterone Gel Consumer Information (Wolters Kluwer)
• Testosterone Patch Consumer Information (Wolters Kluwer)
• Testosterone Solution Consumer Information (Wolters Kluwer)
• Testosterone buccal system Consumer Information (Cerner Multum)
• Testosterone injection Consumer Information (Cerner Multum)
• Testosterone topical Consumer Information (Cerner Multum)
• Androplex Advanced Consumer Information (Micromedex)
• Testosterone Buccal Advanced Consumer Information (Micromedex)
• Testosterone Topical application Advanced Consumer Information (Micromedex)
• Testosterone Transdermal Advanced Consumer Information (Micromedex)
• Testosterone AHFS DI Monographs (ASHP)